Swift Transportation Co., Inc. (NDAQ:SWFT) entered into a definitive merger agreement with an entity formed by Jerry Moyes, the company's largest shareholder, a current Director, and former Chairman of the Board and CEO of Swift, pursuant to which Mr. Moyes and certain of his family members will acquire Swift in an all-cash transaction valued at approximately $2.74 billion. This includes the assumption of approximately $332 million of net debt. Under the terms of the agreement, Swift stockholders will receive $31.55 in cash for each outstanding share of Swift common stock.

Simtek Corporation (NDAQ:SMTK) announced that total revenue for the year ended December 31, 2006, is expected to be approximately $30.6 million, up 194%, compared to revenues of $10.4 million in 2005; meanwhile, the current FY revenue consensus is $29.94 million.

Central Garden & Pet Company (NDAQ:CENT) announced preliminary results for its FY Q1 with a net loss of twelve to fourteen cents per fully diluted share on sales of approximately $320 million. This compares to the previous guidance of approximately breakeven for the quarter; the current consensus stands at $0.00 and $335.78 million.  

Pfizer (NYSE:PFE) plans to maximize revenues from its current in-line portfolio and new products. To expand future revenues, Pfizer will generate cost savings through site rationalization in research and manufacturing, streamlined organizational structures, staff function reductions, increased outsourcing and procurement savings. The company's cost reduction initiatives will result in the elimination of about 10,000 positions or about ten percent of Pfizer's total worldwide workforce by the end of next year. For 2007, Pfizer sees revenues comparable to 2006. The company is seeing an adjusted EPS of $2.18 to $2.25, up to $10B in common stock purchases. For 2008, Pfizer sees revenues comparable to 2006, with an adjusted EPS of $2.31 to $2.45.  

StarTek, Inc. (NYSE:SRT) said total revenues are expected to be approximately $238 million for FY06, versus the consensus $243 million. Q4 revenues are expected to be approximately $59 million, versus the consensus of $64 million. The company expects fully diluted earnings per share in the range of $0.07 to $0.09 per share for the Q4 2006, versus the consensus of $0.16 and $0.38 to $0.40 per share for the full year, versus the consensus of $0.47.

Texas Instruments (NYSE:TXN) reports Q4 EPS of $0.39, one cent better than estimates.  The company's revenues were $3.46 billion versus $3.43 billion consensus. They predict a Q1 EPS of $0.28 to $0.34, versus the consensus of $0.35, with a Q1 revenue of $3.01 to 3.28 billion versus the $3.30 billion consensus.

The board of directors of Gap Inc. (NYSE:GPS) and Paul Pressler announced today that they have mutually agreed that Mr. Pressler will step down from his position as president and CEO of the company, as well as resign his seat on the company's board, effective immediately. Robert J. Fisher, the company's current non-executive chairman of the board of directors, will also serve as president and CEO on an interim basis, effective immediately.

Carl Icahn discloses 6.73% stake in Temple-Inland Inc. (NYSE:TIN).  

ViroPharma Inc. (NDAQ:VPHM) will replace Per-Se Technologies Inc. (NDAQ:PSTI) in the S&P SmallCap 600 after the close of trading on Thursday, January 25. Per-Se is being acquired by S&P 500 constituent McKesson Corp. (NYSE:MCK) in a deal expected to close on or about that date, pending final approvals.

Agree Realty Corp. (NYSE:ADC) will replace CentraCore Properties Trust (NYSE:CPV) in the S&P REIT Composite after the close of trading on Wednesday, January 24. CentraCore is being acquired by The Geo Group, Inc. (NYSE:GEO) in a deal expected to close on or about that date, pending final approvals.

Strategic Hotels & Resorts, Inc. (NYSE:BEE) will replace Reckson Associates Realty Corp. (NYSE:RA) in the S&P REIT Composite after the close of trading on Thursday, January 25. Reckson is being acquired by S&P REIT Composite constituent SL Green Realty Corp. (NYSE:SLG) in a deal expected to close on or about that date, pending final approvals.

Nutrition 21, Inc. (NDAQ:NXXI) announced that daily supplementation with Selenomax, the company's high selenium yeast product, suppressed progression of the human immunodeficiency virus (HIV-1) and improved immune cell CD4 counts in HIV-1 seropositive men and women. These findings are significant because boosting the immune system's CD4 cell count and suppressing viral loads (co-measurements of HIV progression and the goals of HIV treatment), can decrease the likelihood of developing complication of HIV disease and prolong life. Selenomax will be available first at CVS/pharmacy (NYSE:CVS) in all its 6,200 retail stores across the country, including PharmaCare Specialty Pharmacy locations.  

Nitches, Inc. (NDAQ:NICH) reports Q1 EPS of $0.27 compared to $0.14 for the same period last year. Consolidated net sales for the Q1 FY07 increased 141% to $35.4 million versus $14.7 million for the first quarter of 2006.